Sequent Scientific Limited — Important, 11-02-2025: Financial Result Updates

Consolidated financial results for Sequent Scientific Limited show a revenue of ₹3,908.10 crore for the quarter ending December 31, 2024, reflecting a robust growth of 18.66% year-over-year, supported by stronger demand and market expansion. Total income, including other income, reached ₹3,966.50 crore.

Net profit for the quarter stood at ₹64.80 crore, a reversal from a loss of ₹106.80 crore the previous year, indicating improved cost management and operational efficiencies. Earnings Per Share (EPS) improved to ₹0.14 from a loss per share of ₹0.33.

Operational costs increased by approximately 7.53% to ₹3,882.40 crore, driven by higher material costs and employee benefits expenses, which grew as the company scaled operations. The management's cost control measures appear to have stabilized other expenses.

On the balance sheet, equity shares increased slightly to ₹500.60 crore, with total comprehensive income showing a loss of ₹503.80 crore, mainly impacted by currency translation adjustments from international subsidiaries. The company's strategic focus remains on operational efficiency and market expansion, driven by favorable market sentiment.

Investor insight suggests holding the stock, given the positive trends in profitability and revenue growth, tempered by potential currency risks and rising operational costs. Overall, the outlook appears cautiously optimistic as the company navigates its current strategies in a dynamic market environment.